Context The current role of cytoreductive nephrectomy (CN) is controversial. Objective
Review of the available evidence about criteria defining CN optimal candidates. Evidence …

Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and is the eighth leading
cause of cancer in the United States. 1 Worldwide, 400,000 people were diagnosed and …

Background: New technologies are being developed for early detection of multiple types of
cancer simultaneously. To quantify the potential benefit, we estimated reductions in absolute …

Abstract Between December 2005 and October 2009, FDA approved six targeted therapies
shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in …

In recent decades, variability in the incidence and mortality of kidney cancer (KC) has been
reported. This study aimed to compare trends in incidence, mortality, and disability-adjusted …

Abstract Background Immuno-oncology (IO)–based therapies have been approved based
on randomised clinical trials, yet a significant proportion of real-world patients are not …

Background The real-world survival outcomes and prognostic factors among patients
receiving first-line targeted therapy for advanced renal cell carcinoma (aRCC) are not well …

Cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)(resection of the
primary tumor for debulking purposes) was considered to be an important part of oncological …

Background Cytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC) patients
has been common clinical practice due to evidence that resection of the primary tumor …

Introduction Because “real-life” patients often do not meet the strict eligibility criteria of
clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal …